Biomanufacturing Excellence Act of 2025

# Biomanufacturing Excellence Act of 2025 - Summary **What the Bill Does** The Biomanufacturing Excellence Act of 2025 aims to strengthen and expand U.S. biomanufacturing capabilities. Biomanufacturing refers to using living organisms or biological processes to produce medicines, vaccines, chemicals, and other products. While the bill's specific provisions aren't detailed in the available information, legislation of this type typically focuses on supporting domestic production capacity, investing in research and development, and reducing dependence on foreign suppliers for critical biological products. **Who It Affects** This bill would primarily impact pharmaceutical and biotechnology companies, research institutions, and the healthcare industry. It could also affect workers in manufacturing sectors and consumers who rely on medications and vaccines.

The bill's focus on domestic production suggests it's intended to benefit U.S. economic competitiveness and national security in the health sector. **Current Status** The bill was introduced by Representative Chrissy Houlahan (D-PA) in the 119th Congress and is currently in committee review. This means it has not yet been debated or voted on by the full House of Representatives. Further details about specific provisions would likely emerge if the bill advances through the committee process.